Expert industry insights
Practical articles on lab software, data and AI, written by the team that builds software for biotech companies.
CRO LIMS × Biotech
How to choose a LIMS for a biotech CRO
How to choose a LIMS for a CRO, covering sponsor data separation, study and contract workflows, sample traceability, and when a custom build is worth it.
Myroslav SyrkoCOO at CodePhusionBioprocess × Data Systems
Bioprocessing LIMS guide for biotech teams
What a bioprocessing LIMS should manage, where it fits alongside an ELN, historian and MES, the integrations that matter, and when a custom build is worth it.
AI × Lab Software
How to evaluate an AI tool for your lab
How to evaluate AI tools for your biotech lab by checking accuracy, integration, data privacy, validation and total cost before you commit to one of them.
AI × Data Privacy
When self-hosted AI is worth it for biotech
When self-hosted AI for biotech is worth it, and when a commercial API under a BAA is the safer call. Covers API vs self-hosted, RAG vs fine-tuning, and cost.
AI × Compliance
The EU AI Act for biotech in 2026
A 2026 guide to the EU AI Act for biotech, what counts as high risk, why most research AI does not, the proposed delay, and what it means for lab software.
EU × FDA Compliance
EU Annex 11 vs 21 CFR Part 11 explained
EU Annex 11 vs 21 CFR Part 11, covering how the EU and US rules for computerised systems differ and how to build lab software that satisfies both markets.
Compliance × ELN
How to choose a 21 CFR Part 11 compliant ELN
What a 21 CFR Part 11 compliant ELN needs, including audit trails, electronic signatures, access controls, ALCOA+ data integrity, validation, and cloud ELNs.
Branding × Web Presence
How to choose a biotech domain name
How to choose a biotech domain name that signals credibility to investors and partners, from the .com question and naming rules to mistakes and alternatives.
LIMS × Biotech Startups
How to choose a LIMS for biotech startups
A 2026 framework for choosing a LIMS for biotech startups, covering when you need one, what capabilities matter, compliance, budget, and buy versus build.
AI × Drug Discovery
The state of AI in biotech in 2026
A 2026 review of where AI in biotech delivers measurable results, where pilots stalled on data readiness, and the FDA, EMA and EU AI Act shifts coming next.
Building software for modern biotech teams.
Let's review your workflows and identify opportunities for automation, visibility and compliance.